SÃ©bastien Benzekry

List of Publications by Year
in descending order

51 papers	1,490 citations	393982 19 h-index	360668 35 g-index
62 all docs	62 docs citations	62 times ranked	1813 citing authors

#	ARTICLE	IF	CITATIONS
1	Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. PLoS Computational Biology, 2014, 10, e1003800.	1.5	419
2	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. Cancer Research, 2016, 76, 4931-4940.	0.4	132
3	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. PLoS Computational Biology, 2020, 16, e1007178.	1.5	84
4	Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach. Cancer Research, 2016, 76, 535-547.	0.4	73
5	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. Seminars in Cancer Biology, 2015, 35, 53-61.	4.3	67
6	Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology. Clinical Pharmacology and Therapeutics, 2020, 108, 471-486.	2.3	50
7	Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. Journal of Theoretical Biology, 2013, 335, 235-244.	0.8	45
8	Mathematical Modeling of Tumorâ€“Tumor Distant Interactions Supports a Systemic Control of Tumor Growth. Cancer Research, 2017, 77, 5183-5193.	0.4	41
9	Machine Learning and Mechanistic Modeling for Prediction of Metastatic Relapse in Early-Stage Breast Cancer. JCO Clinical Cancer Informatics, 2020, 4, 259-274.	1.0	39
10	Computational Modelling of Metastasis Development in Renal Cell Carcinoma. PLoS Computational Biology, 2015, 11, e1004626.	1.5	37
11	Global Dormancy of Metastases Due to Systemic Inhibition of Angiogenesis. PLoS ONE, 2014, 9, e84249.	1.1	37
12	Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology. Critical Reviews in Oncology/Hematology, 2018, 129, 1-12.	2.0	35
13	Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer. Scientific Reports, 2019, 9, 13018.	1.6	35
14	Host Age Is a Systemic Regulator of Gene Expression Impacting Cancer Progression. Cancer Research, 2015, 75, 1134-1143.	0.4	34
15	Modeling the Impact of Anticancer Agents on Metastatic Spreading. Mathematical Modelling of Natural Phenomena, 2012, 7, 306-336.	0.9	28
16	Design principles for cancer therapy guided by changes in complexity of protein-protein interaction networks. Biology Direct, 2015, 10, 32.	1.9	26
17	Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget, 2017, 8, 23087-23098.	0.8	26
18	A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology. Comptes Rendus Mathematique, 2012, 350, 23-28.	0.1	23

#	Article	IF	Citations
19	Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. Journal of Theoretical Biology, 2013, 320, 86-99.	0.8	21
20	Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1-9.	1.5	21
21	Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas. PLoS ONE, 2017, 12, e0178552.	1.1	20
22	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data. Cancers, 2021, 13, 6210.	1.7	19
23	In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling. Scientific Reports, 2016, 6, 36173.	1.6	17
24	Revisiting Bevacizumabâ€‰+â€‰Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Nonâ€Small Cell Lung Carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 42-50.	1.3	17
25	Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. Molecular Cancer, 2021, 20, 136.	7.9	17
26	Diffeomorphic Matching and Dynamic Deformable Surfaces in 3d Medical Imaging. Computational Methods in Applied Mathematics, 2010, 10, 235-274.	0.4	16
27	Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers. ESAIM: Mathematical Modelling and Numerical Analysis, 2012, 46, 207-237.	0.8	14
28	CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies. AAPS Journal, 2019, 21, 50.	2.2	13
29	Development and Validation of a Prediction Model of Overall Survival in High-Risk Neuroblastoma Using Mechanistic Modeling of Metastasis. JCO Clinical Cancer Informatics, 2021, 5, 81-90.	1.0	12
30	Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3453-E3453.	3.3	11
31	Next generation metronomic chemotherapyâ€”report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€“8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	0.6	10
32	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. JCO Precision Oncology, 2020, 4, 486-491.	1.5	9
33	Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Nonâ€Small Cell Lung Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 577-586.	1.3	8
34	Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach. Oncotarget, 2018, 9, 2574-2590.	0.8	7
35	Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. Anticancer Research, 2019, 39, 3419-3422.	0.5	6
36	Passing to the limit 2Dâ€“1D in a model for metastatic growth. Journal of Biological Dynamics, 2012, 6, 19-30.	0.8	4

#	Article	IF	Citations
37	Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxics modalities: application to the bevacizumab-paclitaxel association in breast cancer models. , 2014, , .		3
38	Capturing the Driving Role of Tumor-Host Crosstalk in a Dynamical Model of Tumor Growth. Bio-protocol, 2015, 5, .	0.2	2
39	Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor. Lecture Notes in Computer Science, 2019, , 87-97.	1.0	1
40	On the growth and dissemination laws in a mathematical model of metastatic growth. ITM Web of Conferences, 2015, 5, 00007.	0.4	0
41	A Mathematical Model for Growing Metastases on Oncologistsâ€™s Service. , 2014, , 331-338.		0
42	Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice. , 2016, , .		0
43	Abstract 2704: Radiotherapy and immunotherapy in cancer: A mathematical model. , 2016, , .		0
44	Abstract 4529: Optimization of the sequence for the administration of bevacizumab in combination with pemetrexed and cisplatin in NSCLC : a pharmacology based in vivo study. , 2017, , .		0
45	Abstract 4264: Mathematical modeling of differential effects of sunitinib on primary tumor and metastatic growth. , 2018, , .		0
46	Title is missing!. , 2020, 16, e1007178.		0
47	Title is missing!. , 2020, 16, e1007178.		0
48	Title is missing!. , 2020, 16, e1007178.		0
49	Title is missing!. , 2020, 16, e1007178.		0
50	Title is missing!. , 2020, 16, e1007178.		0
51	Title is missing!. , 2020, 16, e1007178.		0